These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Liver damage related to immune checkpoint inhibitors. Nishida N; Kudo M Hepatol Int; 2019 May; 13(3):248-252. PubMed ID: 30607787 [TBL] [Abstract][Full Text] [Related]
24. Cutaneous adverse effects of the immune checkpoint inhibitors. Collins LK; Chapman MS; Carter JB; Samie FH Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531 [TBL] [Abstract][Full Text] [Related]
25. [Toxicity of immune checkpoints inhibitors]. Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624 [TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. Psimaras D; Velasco R; Birzu C; Tamburin S; Lustberg M; Bruna J; Argyriou AA J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S74-S85. PubMed ID: 31393660 [TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma. Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873 [TBL] [Abstract][Full Text] [Related]
28. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Sebastiani GD; Scirocco C; Galeazzi M Autoimmun Rev; 2019 Aug; 18(8):805-813. PubMed ID: 31176871 [TBL] [Abstract][Full Text] [Related]
29. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells. Anderson R; Theron AJ; Rapoport BL Front Immunol; 2019; 10():2254. PubMed ID: 31616428 [TBL] [Abstract][Full Text] [Related]
30. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Cortellini A; Buti S; Agostinelli V; Bersanelli M Semin Oncol; 2019; 46(4-5):362-371. PubMed ID: 31727344 [TBL] [Abstract][Full Text] [Related]
31. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy. Narváez J; Juarez-López P; LLuch J; Narváez JA; Palmero R; García Del Muro X; Nolla JM; Domingo-Domenech E Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042 [TBL] [Abstract][Full Text] [Related]
32. Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment. Paolini L; Poli C; Blanchard S; Urban T; Croué A; Rousselet MC; Le Roux S; Labarrière N; Jeannin P; Hureaux J J Immunother Cancer; 2018 Jun; 6(1):52. PubMed ID: 29898781 [TBL] [Abstract][Full Text] [Related]
33. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review. Abdel-Wahab N; Shah M; Lopez-Olivo MA; Suarez-Almazor ME Ann Intern Med; 2018 Jan; 168(2):121-130. PubMed ID: 29297009 [TBL] [Abstract][Full Text] [Related]
34. Management of immune related adverse events induced by immune checkpoint inhibition. Teufel A; Zhan T; Härtel N; Bornschein J; Ebert MP; Schulte N Cancer Lett; 2019 Aug; 456():80-87. PubMed ID: 31051213 [TBL] [Abstract][Full Text] [Related]
35. [IMMUNOTHERAPY WITH CHECKPOINT INHIBITORS (ICPI) AND IMMUNE RELATED ADVERSE EVENTS (IRAE'S)]. Ben Zvi C; Ehrenfeld M; Shoenfeld Y Harefuah; 2020 Jul; 159(7):508-515. PubMed ID: 32720769 [TBL] [Abstract][Full Text] [Related]
36. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Kumar V; Chaudhary N; Garg M; Floudas CS; Soni P; Chandra AB Front Pharmacol; 2017; 8():49. PubMed ID: 28228726 [TBL] [Abstract][Full Text] [Related]
37. Immune-related cutaneous adverse events due to checkpoint inhibitors. Wang E; Kraehenbuehl L; Ketosugbo K; Kern JA; Lacouture ME; Leung DYM Ann Allergy Asthma Immunol; 2021 Jun; 126(6):613-622. PubMed ID: 33609771 [TBL] [Abstract][Full Text] [Related]
38. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683 [TBL] [Abstract][Full Text] [Related]
39. Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. Choi J; Lee SY Immune Netw; 2020 Feb; 20(1):e9. PubMed ID: 32158597 [TBL] [Abstract][Full Text] [Related]
40. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Cousin S; Italiano A Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]